Gene · 10457
GPNMB: glycoprotein nmb
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GPNMB: glycoprotein nmb. Genes, record 10457. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10457
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q14956 | Transmembrane glycoprotein NMB | 572 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents97
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4772193 A1 | 2026-07-08 | 209 | Q14956 | Espacenet |
| EP 4772536 A1 | 2026-07-08 | 209 | Q14956 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10510 | Q14956 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 1600 | Q14956 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 10858 | Q14956 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 6152 | Q14956 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1774 | Q14956 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6533 | Q14956 | Espacenet |
| JP 2025527204 A | 2025-08-20 | 1 | Q14956 | Espacenet |
| WO 2025166040 A1 | 2025-08-07 | 241 | Q14956 | Espacenet |
1 to 10 of 97
See all 97 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials11
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT03473691 | GLEMBATUMUMAB VEDOTIN | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT03326258 | GLEMBATUMUMAB VEDOTIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03067935 | GLEMBATUMUMAB VEDOTIN | ClinicalTrials.gov | ||
| NCT02713828 | GLEMBATUMUMAB VEDOTIN | PHASE1/PHASE2 | 2019-07-16 | ClinicalTrials.gov |
| NCT02487979 | GLEMBATUMUMAB VEDOTIN | PHASE2 | 2018-10-15 | ClinicalTrials.gov |
| NCT02363283 | GLEMBATUMUMAB VEDOTIN | PHASE2 | 2020-08-21 | ClinicalTrials.gov |
| NCT02302339 | GLEMBATUMUMAB VEDOTIN | PHASE2 | 2019-09-06 | ClinicalTrials.gov |
| NCT01997333 | GLEMBATUMUMAB VEDOTIN | PHASE2 | 2019-03-08 | ClinicalTrials.gov |
| NCT01156753 | GLEMBATUMUMAB VEDOTIN | PHASE2 | ClinicalTrials.gov | |
| NCT00704158 | GLEMBATUMUMAB VEDOTIN | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsNIH grants1,518
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GPNMB papers | Newest fiscal year |
|---|---|---|---|
| ZIABC011028 | Clinical Studies of the Molecular Genetic Basis of Kidney Cancer | 11 | 2025 |
| ZIDBC011089 | Clinical Nursing and Data Management Core | 10 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 9 | 2025 |
| ZIABC011043 | Molecular Therapeutics of Kidney Cancer: MET Gene and BHD Gene | 7 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| ZICBC011044 | Tissue Processing-Sequencing Facility | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| ZIABC011038 | Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase Gene | 5 | 2025 |
| P30AG066511 | Goizueta Alzheimer's Disease Research Center | 4 | 2025 |
| P30AG066519 | The Alzheimer's Disease Research Center at the University of California, Irvine | 4 | 2025 |
1 to 10 of 1,518Source NIH's project files
See all 1,518 nih grantsPapers2,043
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| High expression of glycoprotein non-metastatic melanoma protein B is associated with resistance to neoadjuvant chemotherapy in triple-negative breast cancer. | Histol Histopathol | 2026 | 42806768 | PubTator, text mining | PubMed |
| Explainable Artificial Intelligence and Gene-Network Analysis Prioritise a TREM2/LGALS3/GPNMB Scar-Associated Macrophage Programme in Human Liver Cirrhosis. | Int J Mol Sci | 2026 | 42794453 | PubTator, text mining | PubMed |
| Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. | Histopathology | 2026 | 42791032 | PubTator, text mining | PubMed |
| Disentangling the Cellular Composition of FLCN-Mutated Tumors in Birt-Hogg-Dubé Syndrome by Spatial Transcriptomics. | Mod Pathol | 2026 | 42754233 | PubTator, text mining | PubMed |
| An Underrecognized Cause of Recurrent Spontaneous Pneumothorax: Birt-Hogg-Dubé Syndrome With Isolated Pulmonary Manifestation. | Respirol Case Rep | 2026 | 42719447 | PubTator, text mining | PubMed |
| Multi-omics mapping of PSC genetic risk to a high TWAS-active JAML+ lipid-associated macrophage program: bridging single-cell heterogeneity, spatial fibrotic niches, and machine learning selection. | Front Cell Dev Biol | 2026 | 42707798 | PubTator, text mining | PubMed |
| [Birt-Hogg-Dubé syndrome-associated renal tumors: a clinicopathological and molecular genetic analysis of ten cases]. | Zhonghua Bing Li Xue Za Zhi | 2026 | 42706109 | PubTator, text mining | PubMed |
| Longitudinal assessment of glomerular and tubular kidney function after COVID-19: a prospective cohort study. | Scand J Clin Lab Invest | 2026 | 42690026 | PubTator, text mining | PubMed |
| Aggressive high-grade papillary-patterned renal cell carcinomas harboring FLCN mutations: expanding the clinicopathological spectrum in Birt-Hogg-Dubé syndrome and sporadic cases. | Virchows Arch | 2026 | 42687010 | PubTator, text mining | PubMed |
| GPNMB promotes double-membrane vesicle accumulation and facilitates structural protein transport during PEDV infection. | Virulence | 2026 | 42678062 | PubTator, text mining | PubMed |
1 to 10 of 2,043
See all 2,043 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10457
GET https://conductscience.org/api/genes/v1/10457/patents?page=2